X0609 4 2026-05-20 0 0001304492 Anterix Inc. ATEX 0001571521 Kuhn Thomas R. false 3 GARRET MOUNTAIN PLAZA SUITE 401 WOODLAND PARK NJ 07424 1 0 0 1 Executive Chairman 0 Common Stock 2026-05-20 4 A 0 2791 A 19385 D Common Stock 2026-06-18 4 S 0 1654 79.52 D 17731 D Common Stock 2026-08-24 4 M 0 10000 33.62 A 27731 D Common Stock 2026-08-24 4 S 0 4392 88.182 D 23339 D Common Stock 2026-08-24 4 S 0 4418 89.1187 D 18921 D Common Stock 2026-08-24 4 S 0 790 90.0009 D 18131 D Common Stock 2026-08-24 4 S 0 400 91.01 D 17731 D Stock Option (Right to Buy) 33.62 2026-08-24 4 M 0 10000 0 D 2034-01-02 Common Stock 10000 48998 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The RSU vests in full on the earlier of: (i) May 20, 2027, and (ii) the Issuer's next annual stockholder meeting. These shares of Common Stock were automatically sold in a non-discretionary transaction to cover tax withholding obligations upon the settlement of certain time-based RSU awards. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.67 to $88.66, inclusive. The Reporting Person has provided to the Issuer and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.71 to $89.67, inclusive. The Reporting Person has provided to the Issuer and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.79 to $90.51, inclusive. The Reporting Person has provided to the Issuer and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. 1/3rd of the option shares vest and become exercisable on January 2, 2025, with the remaining option shares vesting in two equal annual installments thereafter. s/ Gena L. Ashe, Attorney-in-Fact 2026-08-26